Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001090862 | SCV001246620 | uncertain significance | not provided | 2019-07-01 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV001090862 | SCV001446591 | likely pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Paris Brain Institute, |
RCV001391505 | SCV001450953 | pathogenic | Hereditary spastic paraplegia 4 | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001391505 | SCV003221062 | uncertain significance | Hereditary spastic paraplegia 4 | 2022-07-15 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with SPAST-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 871091). This variant is not present in population databases (gnomAD no frequency). This sequence change affects codon 391 of the SPAST mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the SPAST protein. This variant also falls at the last nucleotide of exon 8, which is part of the consensus splice site for this exon. |